Latest:
Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer
Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Alexandre A. Jácome, MD, PhD
Latest:
Test for Summarization
Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.
Jason Westin MD, FACP
Latest:
Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Jason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Jing Christine Ye, MD, MSc
Latest:
BCMA Bispecifics in the Clinic: Data, Toxicities, and Real-World Experience
Panelists discuss how dual-targeting bispecific therapies, exemplified by JNJ-78934804 (targeting BCMA and GPRC5D), show early potential to redefine treatment paradigms in heavily pretreated multiple myeloma, with impressive response rates and manageable safety profiles.
Jeanne Fourie Zirkelbach, PhD
Latest:
FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhD
Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.
Colin Vale, MD
Latest:
JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis
Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.
Bradford (Brad) S. Hoppe, MD, MPH
Latest:
Dr Hoppe on Outcomes of the CheckMate 744 Trial in Hodgkin Lymphoma
Bradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.